WINTON GROUP Ltd Purchases Shares of 102,632 Integra LifeSciences Holdings Corporation $IART

Posted by George Bondi on Sep 12th, 2026

WINTON GROUP Ltd purchased a new position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART – Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 102,632 shares of the life sciences company’s stock, valued at approximately $1,843,000. WINTON GROUP Ltd owned approximately 0.13% of Integra LifeSciences as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Integrated Wealth Concepts LLC acquired a new position in shares of Integra LifeSciences during the 2nd quarter valued at $84,000. Corient Private Wealth LP grew its holdings in Integra LifeSciences by 66.9% in the second quarter. Corient Private Wealth LP now owns 22,749 shares of the life sciences company’s stock worth $409,000 after purchasing an additional 9,120 shares during the period. California State Teachers Retirement System grew its holdings in Integra LifeSciences by 2,059.1% in the second quarter. California State Teachers Retirement System now owns 1,358,620 shares of the life sciences company’s stock worth $24,401,000 after purchasing an additional 1,295,695 shares during the period. Wellington Management Group LLP increased its stake in Integra LifeSciences by 12.4% in the second quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock valued at $26,241,000 after purchasing an additional 160,814 shares in the last quarter. Finally, Public Employees Retirement System of Ohio bought a new stake in Integra LifeSciences in the second quarter valued at $82,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Stock Down 0.3%

Shares of NASDAQ IART opened at $15.50 on Friday. The stock has a market capitalization of $1.21 billion, a P/E ratio of -172.20, a P/E/G ratio of 0.80 and a beta of 1.21. The company has a 50-day moving average price of $17.59 and a 200-day moving average price of $14.60. Integra LifeSciences Holdings Corporation has a 1 year low of $8.70 and a 1 year high of $20.49. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11.

Integra LifeSciences (NASDAQ:IART – Get Free Report) last posted its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The company had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, equities research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on IART shares. Wall Street Zen cut shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research note on Thursday, June 18th. UBS Group started coverage on Integra LifeSciences in a report on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 price target on the stock. Finally, Truist Financial raised their price objective on Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. One equities research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $18.86.

Get Our Latest Stock Analysis on IART

Integra LifeSciences Profile

(Free Report)

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.